: Uses a highly stable oxime bond to prevent the premature release of the toxin into the bloodstream, which reduces systemic side effects.
ARX788 is a site-specific ADC designed to target and HER2-low cancers. Unlike traditional therapies, it uses a unique non-natural amino acid technology to link a potent toxin directly to an antibody, ensuring the "payload" is delivered specifically to cancer cells while sparing healthy tissue. 1. Clinical Applications & Efficacy ABP-788.mp4
: Recent data from the ACE-Breast-06 study showed that ARX788 can cross the blood-brain barrier, providing a 25% objective response rate for patients with active brain metastases. : Uses a highly stable oxime bond to
: In the ACE-Breast-02 trial , ARX788 significantly improved progression-free survival (PFS) to 11.3 months compared to 8.2 months for standard treatments. The "guide" in the video likely explains the :
The "guide" in the video likely explains the :